Intersecting Layers of Fragility: Anemia and Schistosomiasis
Main Article Content
Abstract
Anemia and schistosomiasis are intertwined global health challenges, disproportionately affecting vulnerable populations in low-income regions. Anemia, with a global prevalence of 24.3%, affects over 1.92 billion people, particularly women and children under five. Schistosomiasis, a neglected tropical disease, afflicts approximately 250 million individuals, primarily in tropical and subtropical areas. The intersection of these conditions is exacerbated by layers of fragility, including poverty, geographic isolation, and demographic factors such as age and gender. Women, especially those pregnant, and children are particularly vulnerable due to the compounded effects of iron deficiency, parasitic infections, and inadequate access to healthcare.
Iron metabolism plays a crucial role in the pathophysiology of anemia in schistosomiasis. The parasite-induced blood loss and iron sequestration in the liver and spleen contribute significantly to blood deficiency. Current treatments, primarily praziquantel, do not address long-term damage or the complex interplay between anemia and parasitic infection, underscoring the need for novel therapeutic strategies targeting iron metabolism and fibrosis.
This review highlights the importance of addressing these intersecting higher hierarchical levels and layers of vulnerabilities to molecules, through a multifaceted approach that includes improved diagnostics, comprehensive treatment strategies, and sustained research efforts. Tackling the ecological, social, and medical determinants of these diseases is essential for breaking the cycle of poverty and disease, ultimately improving health outcomes in the most affected and structurally fragile populations.
Article Details
How to Cite
LAMARÃO, Flávia R. M.; AYRES-SILVA, Jackline P..
Intersecting Layers of Fragility: Anemia and Schistosomiasis.
Medical Research Archives, [S.l.], v. 13, n. 5, june 2025.
ISSN 2375-1924.
Available at: <https://esmed.org/MRA/mra/article/view/6480>. Date accessed: 23 june 2025.
doi: https://doi.org/10.18103/mra.v13i5.6480.
Section
Review Articles
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
1. GBD 2021 Anaemia Collaborators. Prevalence, years lived with disability, and trends in anaemia burden by severity and cause, 1990-2021: findings from the Global Burden of Disease Study 2021. Lancet Haematol. 2023;10(9):e713-e734. doi:10.1016/S2352-3026(23)00160-6
2. Kassebaum NJ, Jasrasaria R, Naghavi M, et al. A systematic analysis of global anemia burden from 1990 to 2010. Blood. 2014;123(5):615-624. doi:10.1182/blood-2013-06-508325
3. Stevens GA, Paciorek CJ, Flores-Urrutia MC, et al. National, regional, and global estimates of anaemia by severity in women and children for 2000–19: a pooled analysis of population-representative data. Lancet Glob Health. 2022;10(5):e627-e639. doi:10.1016/S2214-109X(22)00084-5
4. World Health Organization (WHO), THE GLOBAL HEALTH OBSERVATORY (GHO). Schistosomiasis. Accessed May 16, 2024. https://www.who.int/data/gho/data/themes/topics/schistosomiasis
5. King CH, Galvani AP. Underestimation of the global burden of schistosomiasis. The Lancet. 2018;391(10118):307-308. doi:10.1016/S0140-6736(18)30098-9
6. Kassebaum NJ. The Global Burden of Anemia. Hematol Oncol Clin North Am. 2016;30(2):247-308. doi:10.1016/j.hoc.2015.11.002
7. Lanier JB, Park JJ, Callahan RC. Anemia in Older Adults. Am Fam Physician. 2018;98(7):437-442.
8. Araujo Costa E, De Paula Ayres-Silva J. Global profile of anemia during pregnancy versus country income overview: 19 years estimative (2000–2019). Ann Hematol. Published online May 26, 2023. doi:10.1007/s00277-023-05279-2
9. Kinyoki D, Osgood-Zimmerman AE, Bhattacharjee NV, et al. Anemia prevalence in women of reproductive age in low- and middle-income countries between 2000 and 2018. Nat Med. 2021;27(10):1761-1782. doi:10.1038/s41591-021-01498-0
10. Sun J, Wu H, Zhao M, Magnussen CG, Xi B. Prevalence and changes of anemia among young children and women in 47 low- and middle-income countries, 2000-2018. EClinicalMedicine. 2021;41:101136. doi:10.1016/j.eclinm.2021.101136
11. Leir SA, Foot O, Jeyaratnam D, Whyte MB. Schistosomiasis and associated iron-deficiency anaemia presenting decades after immigration from sub-Saharan Africa. BMJ Case Rep. 2019;12(4):e227564. doi:10.1136/bcr-2018-227564
12. Grotto HZW. Fisiologia e metabolismo do ferro. Rev Bras Hematol E Hemoter. 2010;32:08-17. doi:10.1590/S1516-84842010005000050
13. Koury MJ. Abnormal erythropoiesis and the pathophysiology of chronic anemia. Blood Rev. 2014;28(2):49-66. doi:10.1016/j.blre.2014.01.002
14. Grotto HZW. Metabolismo do ferro: uma revisão sobre os principais mecanismos envolvidos em sua homeostase. Rev Bras Hematol E Hemoter. 2008;30(5). doi:10.1590/S1516-848420080005 00012
15. Dugdale M. ANEMIA. Obstet Gynecol Clin North Am. 2001;28(2):363-382. doi:10.1016/S0889-8545(05)70206-0
16. Vaulont S. Métabolisme du fer. Arch Pédiatrie. 2017;24(5):5S32-5S39. doi:10.1016/S0929-693X(17)24007-X
17. Camaschella Clara. Iron-Deficiency Anemia. N Engl J Med. 2015;372(19):1832-1843. doi:10.1056/NE JMra1401038
18. Milman N, Taylor CL, Merkel J, Brannon PM. Iron status in pregnant women and women of reproductive age in Europe. Am J Clin Nutr. 2017;106(Suppl 6):1655S-1662S. doi:10.3945/ajcn.117.156000
19. WHO Guideline on Use of Ferritin Concentrations to Assess Iron Status in Individuals and Populations. World Health Organization; 2020. Accessed June 3, 2022. http://www.ncbi.nlm.nih.gov/books/NBK569880/
20. Cappellini MD, Santini V, Braxs C, Shander A. Iron metabolism and iron deficiency anemia in women. Fertil Steril. 2022;118(4):607-614. doi:10.1016/j.fertnstert.2022.08.014
21. Gulec S, Anderson GJ, Collins JF. Mechanistic and regulatory aspects of intestinal iron absorption. Am J Physiol-Gastrointest Liver Physiol. 2014;307(4): G397-G409. doi:10.1152/ajpgi.00348.2013
22. Rouault TA. The role of iron regulatory proteins in mammalian iron homeostasis and disease. Nat Chem Biol. 2006;2(8):406-414. doi:10.1038/nchembio807
23. Hentze MW, Muckenthaler MU, Galy B, Camaschella C. Two to Tango: Regulation of Mammalian Iron Metabolism. Cell. 2010;142(1):24-38. doi:10.1016/j.cell.2010.06.028
24. Muckenthaler MU, Rivella S, Hentze MW, Galy B. A Red Carpet for Iron Metabolism. Cell. 2017;168(3):344-361. doi:10.1016/j.cell.2016.12.034
25. Naigamwalla DZ, Webb JA, Giger U. Iron deficiency anemia. Can Vet J Rev Veterinaire Can. 2012;53(3):250-256.
26. Cappellini MD, Musallam KM, Taher AT. Iron deficiency anaemia revisited. J Intern Med. 2020;287(2):153-170. doi:10.1111/joim.13004
27. Pagani A, Nai A, Silvestri L, Camaschella C. Hepcidin and Anemia: A Tight Relationship. Front Physiol. 2019;10. doi:10.3389/fphys.2019.01294
28. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization. Science. 2004;306(5704):2090-2093. doi:10.1126/science.1104742
29. The mutual control of iron and erythropoiesis - Camaschella - 2016 - International Journal of Laboratory Hematology - Wiley Online Library. Accessed May 22, 2024. https://onlinelibrary.wiley.com/doi/10.1111/ijlh.12505
30. Scholl TO. Maternal iron status: relation to fetal growth, length of gestation, and iron endowment of the neonate. Nutr Rev. 2011;69(suppl_1):S23-S29. doi:10.1111/j.1753-4887.2011.00429.x
31. Hercberg S, Preziosi P, Galan P. Iron deficiency in Europe. Public Health Nutr. 2001;4(2B):537-545. doi:10.1079/phn2001139
32. CDC. About Schistosomiasis. Schistosomiasis. March 11, 2024. Accessed May 23, 2024. https://www.cdc.gov/schistosomiasis/about/index.html
33. Ending the neglect to attain the Sustainable Development Goals: A road map for neglected tropical diseases 2021–2030. Accessed May 23, 2024. https://www.who.int/publications/i/item/9789240010352
34. Wang L, Wu X, Li X, et al. Imported Schistosomiasis: A New Public Health Challenge for China. Front Med. 2020;7:553487. doi:10.3389/fmed.2020.553487
35. Kumar V, Gryseels B. Use of praziquantel against schistosomiasis: a review of current status. Int J Antimicrob Agents. 1994;4(4):313-320. doi:10.1016/0924-8579(94)90032-9
36. Fallon PG, Tao LF, Ismail MM, Bennett JL. Schistosome resistance to praziquantel: Fact or artifact? Parasitol Today. 1996;12(8):316-320. doi:10.1016/0169-4758(96)10029-6
37. Santos ET. Schistosoma mansoni: avaliação da fibrose hepática em camundongos submetidos à quimioterapia e reinfectados. Published online 2011. Accessed June 27, 2024. https://www.arca.fiocruz.br/handle/icict/5833
38. Meister I, Leonidova A, Kovač J, Duthaler U, Keiser J, Huwyler J. Development and validation of an enantioselective LC–MS/MS method for the analysis of the anthelmintic drug praziquantel and its main metabolite in human plasma, blood and dried blood spots. J Pharm Biomed Anal. 2016;118:81-88. doi:10.1016/j.jpba.2015.10.011
39. Olveda RM, Acosta LP, Tallo V, et al. Efficacy and safety of praziquantel for the treatment of human schistosomiasis during pregnancy: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2016;16(2):199-208. doi:10.1016/S1473-3099(15)00345-X
40. Malhado M, Pinto DP, Silva ACA, et al. Preclinical pharmacokinetic evaluation of praziquantel loaded in poly (methyl methacrylate) nanoparticle using a HPLC–MS/MS. J Pharm Biomed Anal. 2016;117:405-412. doi:10.1016/j.jpba.2015.09.023
41. Jauréguiberry S, Paris L, Caumes E. Acute schistosomiasis, a diagnostic and therapeutic challenge. Clin Microbiol Infect. 2010;16(3):225-231. doi:10.1111/j.1469-0691.2009.03131.x
42. Olds GR, King C, Hewlett J, et al. Double-blind placebo-controlled study of concurrent administration of albendazole and praziquantel in schoolchildren with schistosomiasis and geohelminths. J Infect Dis. 1999;179(4):996-1003. doi:10.1086/314686
43. Othman AA, Soliman RH. Schistosomiasis in Egypt: A never-ending story? Acta Trop. 2015;148:179-190. doi:10.1016/j.actatropica.2015.04.016
44. Gönnert R, Andrews P. Praziquantel, a new board-spectrum antischistosomal agent. Z Parasitenkd Berl Ger. 1977;52(2):129-150. doi:10.1007/BF00389899
45. Schistosomiasis Chemotherapy - Thétiot‐Laurent - 2013 - Angewandte Chemie International Edition - Wiley Online Library. Accessed June 20, 2024. https://onlinelibrary.wiley.com/doi/abs/10.1002/anie.201208390
46. Frezza TF, Gremião MPD, Zanotti-Magalhães EM, Magalhães LA, de Souza ALR, Allegretti SM. Liposomal-praziquantel: Efficacy against Schistosoma mansoni in a preclinical assay. Acta Trop. 2013;128(1):70-75. doi:10.1016/j.actatropica.2013.06.011
47. Frezza TF, de Souza ALR, Prado CCR, et al. Effectiveness of hyperbaric oxygen for experimental treatment of schistosomiasis mansoni using praziquantel-free and encapsulated into liposomes: assay in adult worms and oviposition. Acta Trop. 2015;150:182-189. doi:10.1016/j.actatropica.2015.07.022
48. Arrúa EC, Ferreira MJG, Salomon CJ, Nunes TG. Elucidating the guest-host interactions and complex formation of praziquantel and cyclodextrin derivatives by 13C and 15N solid-state NMR spectroscopy. Int J Pharm. 2015;496(2):812-821. doi:10.1016/j.ijpharm.2015.11.026
49. Ra ER, Ha T. Novel therapeutic and prevention approaches for schistosomiasis: review. J Adv Res. 2013;4(5). doi:10.1016/j.jare.2012.05.002
50. Dayan AD. Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics. Acta Trop. 2003;86(2):141-159. doi:10.1016/S0001-706X(03)00031-7
51. Olds GR. Administration of Praziquantel to pregnant and lactating women. Prep Control Schistosomiasis Soil-Transm Helminthiasis Twenty-First Century. 2003;86(2):185-195. doi:10.1016/S0001-706X (03)00033-0
52. Dinora GE, Julio R, Nelly C, Lilian YM, Cook HJ. In vitro characterization of some biopharmaceutical properties of praziquantel. Int J Pharm. 2005;295(1):93-99. doi:10.1016/j.ijpharm.2005.01.033
53. Cheng L, Guo S, Wu W. Characterization and in vitro release of praziquantel from poly(ɛ-caprolactone) implants. Int J Pharm. 2009;377(1):112-119. doi:10.1016/j.ijpharm.2009.05.007
54. Katz N, Coelho PMZ. Clinical therapy of schistosomiasis mansoni: The Brazilian contribution. Schisto Res Braz. 2008;108(2):72-78. doi:10.1016/j.actatropica.2008.05.006
55. Novaes MRCG, Souza JP de, Araújo HC de. Síntese do anti-helmíntico praziquantel,a partir da glicina. Quím Nova. 1999;22.
56. Cioli D, Pica-Mattoccia L, Basso A, Guidi A. Schistosomiasis control: praziquantel forever? Mol Biochem Parasitol. 2014;195(1):23-29. doi:10.1016/j.molbiopara.2014.06.002
57. Lim RM, Arme TM, Pedersen AB, Webster JP, Lamberton PHL. Defining schistosomiasis hotspots based on literature and shareholder interviews. Trends Parasitol. 2023;39(12):1032-1049. doi:10.1016/j.pt.2023.09.006
58. Ponzo E, Midiri A, Manno A, Pastorello M, Biondo C, Mancuso G. Insights into the epidemiology, pathogenesis, and differential diagnosis of schistosomiasis. Eur J Microbiol Immunol. 2024;14(2): 86-96. doi:10.1556/1886.2024.00013
59. Friedman JF, Kanzaria HK, McGarvey ST. Human schistosomiasis and anemia: the relationship and potential mechanisms. Trends Parasitol. 2005;21(8): 386-392. doi:10.1016/j.pt.2005.06.006
60. Warren KS, Mahmoud AA, Cummings P, Murphy DJ, Houser HB. Schistosomiasis mansoni in Yemeni in California: duration of infection, presence of disease, therapeutic management. Am J Trop Med Hyg. 1974;23(5):902-909. doi:10.4269/ajtmh.1974.23.902
61. Chabasse D, Bertrand G, Leroux JP, Gauthey N, Hocquet P. [Developmental bilharziasis caused by Schistosoma mansoni discovered 37 years after infestation]. Bull Soc Pathol Exot Filiales. 1985;78(5): 643-647.
62. Mawa PA, Kincaid-Smith J, Tukahebwa EM, Webster JP, Wilson S. Schistosomiasis Morbidity Hotspots: Roles of the Human Host, the Parasite and Their Interface in the Development of Severe Morbidity. Front Immunol. 2021;12:635869. doi:10.3389/fimmu.2021.635869
63. Trippler L, Hattendorf J, Ali SM, et al. Novel tools and strategies for breaking schistosomiasis transmission: study protocol for an intervention study. BMC Infect Dis. 2021;21(1):1024. doi:10.1186/s12879-021-06620-8
64. Díaz AV, Walker M, Webster JP. Reaching the World Health Organization elimination targets for schistosomiasis: the importance of a One Health perspective. Philos Trans R Soc Lond B Biol Sci. 2023;378(1887):20220274. doi:10.1098/rstb.2022.0274
65. Lombardo FC, Pasche V, Panic G, Endriss Y, Keiser J. Life cycle maintenance and drug-sensitivity assays for early drug discovery in Schistosoma mansoni. Nat Protoc. 2019;14(2):461-481. doi:10.1038/s41596-018-0101-y
66. Bergquist R, Zhou XN, Rollinson D, Reinhard-Rupp J, Klohe K. Elimination of schistosomiasis: the tools required. Infect Dis Poverty. 2017;6(1):158. doi:10.1186/s40249-017-0370-7
67. Kajihara N, Hirayama K. The War against a Regional Disease in Japan A History of the Eradication of Schistosomiasis japonica. Trop Med Health. 2011;39(1 Suppl 1):3-44. doi:10.2149/tmh.39-1-suppl_1-3
68. Limpanont Y, Phuphisut O, Reamtong O, Adisakwattana P. Recent advances in Schistosoma mekongi ecology, transcriptomics and proteomics of relevance to snail control. Acta Trop. 2020;202:105244. doi:10.1016/j.actatropica.2019.105244
69. Souza CP de. Molluscicide control of snail vectors of schistosomiasis. Mem Inst Oswaldo Cruz. 1995;90:165-168.
doi:10.1590/S0074-02761995000200007
70. Yuan Y, Xu XJ, Dong HF, Jiang MS, Zhu HG. Transmission control of schistosomiasis japonica: implementation and evaluation of different snail control interventions. Acta Trop. 2005;96(2):191-197. doi:10.1016/j.actatropica.2005.07.014
71. Sun LP, Wang W, Hong QB, et al. Approaches being used in the national schistosomiasis elimination programme in China: a review. Infect Dis Poverty. 2017;6(1):55. doi:10.1186/s40249-017-0271-9
72. Zheng L, Deng L, Zhong Y, Wang Y, Guo W, Fan X. Molluscicides against the snail-intermediate host of Schistosoma: a review. Parasitol Res. 2021;120(10):3355-3393. doi:10.1007/s00436-021-07288-4
73. Cardoso DM, Araújo AF de, Gonçalves S de A, et al. Aspectos espaciais, sociodemográficos, clínicos e temporais da esquistossomose no estado de Minas Gerais entre os anos de 2011 e 2020 / Spatial, socio-demographic, clinical and temporal aspects of schistosomiasis in the state of Minas Gerais between the years of 2011 and 2020. Braz J Dev. 2021;7(8):78130-78143. doi:10.34117/bjdv7n8-165
74. McDonald CJ, Jones MK, Wallace DF, Summerville L, Nawaratna S, Subramaniam VN. Increased iron stores correlate with worse disease outcomes in a mouse model of schistosomiasis infection. PloS One. 2010;5(3):e9594. doi:10.1371/journal.pone.0009594
75. World Health Organization, ed. The Clinical Use of Blood in Medicine, Obstetrics, Paediatrics, Surgery & Anaesthesia, Trauma & Burns. World Health Organization; 2001. https://iris.who.int/handle/10665/42397
76. Scholl TO. Maternal iron status: relation to fetal growth, length of gestation, and iron endowment of the neonate. Nutr Rev. 2011;69 Suppl 1:S23-29. doi:10.1111/j.1753-4887.2011.00429.x
77. WHO, ed. The Clinical Use of Blood in Medicine, Obstetrics, Paediatrics, Surgery & Anaesthesia, Trauma & Burns. World Health Organization; 2001.
78. Farid Z, Patwardhan VN, Darby WJ. Parasitism and anemia. Am J Clin Nutr. 1969;22(4):498-503. doi:10.1093/ajcn/22.4.498
79. Friis H, Mwaniki D, Omondi B, et al. Effects on haemoglobin of multi-micronutrient supplementation and multi-helminth chemotherapy: a randomized, controlled trial in Kenyan school children. Eur J Clin Nutr. 2003;57(4):573-579. doi:10.1038/sj.ejcn.1601568
80. Latham MC, Stephenson LS, Hall A, Wolgemuth JC, Elliot TC, Crompton DW. Parasitic infections, anaemia and nutritional status: a study of their interrelationships and the effect of prophylaxis and treatment on workers in Kwale District, Kenya. Trans R Soc Trop Med Hyg. 1983;77(1):41-48. doi:10.1016/0035-9203(83)90009-3
81. Beasley NM, Tomkins AM, Hall A, et al. The impact of population level deworming on the haemoglobin levels of schoolchildren in Tanga, Tanzania. Trop Med Int Health TM IH. 1999;4(11):744-750. doi:10.1046/j.1365-3156.1999.00486.x
82. Taylor M, Jinabhai CC, Couper I, Kleinschmidt I, Jogessar VB. The effect of different anthelmintic treatment regimens combined with iron supplementation on the nutritional status of schoolchildren in KwaZulu-Natal, South Africa: a randomized controlled trial. Trans R Soc Trop Med Hyg. 2001;95(2):211-216. doi:10.1016/s0035-9203(01)90171-3
83. Sturrock RF, Kariuki HC, Thiongo FW, et al. Schistosomiasis mansoni in Kenya: relationship between infection and anaemia in schoolchildren at the community level. Trans R Soc Trop Med Hyg. 1996;90(1):48-54.
doi:10.1016/s0035-9203(96)90477-0
84. Befidi-Mengue RN, Ratard RC, Beltran G, et al. Impact of Schistosoma haematobium infection and of praziquantel treatment on anaemia of primary school children in Bertoua, Cameroon. J Trop Med Hyg. 1993;96(4):225-230.
85. Stephenson LS, Kinoti SN, Latham MC, Kurz KM, Kyobe J. Single dose metrifonate or praziquantel treatment in Kenyan children. I. Effects on Schistosoma haematobium, hookworm, hemoglobin levels, splenomegaly, and hepatomegaly. Am J Trop Med Hyg. 1989;41(4):436-444. doi:10.4269/ajtmh.1989.41.436
86. McGarvey ST, Aligui G, Graham KK, Peters P, Olds GR, Olveda R. Schistosomiasis japonica and childhood nutritional status in northeastern Leyte, the Philippines: a randomized trial of praziquantel versus placebo. Am J Trop Med Hyg. 1996;54(5):498-502. doi:10.4269/ajtmh.1996.54.498
87. Farid Z, Bassily S, Schulert AR, et al. Blood loss in chronic Schistosoma mansoni infection in Egyptian farmers. Trans R Soc Trop Med Hyg. 1967;61(5): 621-625.
doi:10.1016/0035-9203(67)90124-1
88. Tatala S, Svanberg U, Mduma B. Low dietary iron availability is a major cause of anemia: a nutrition survey in the Lindi District of Tanzania. Am J Clin Nutr. 1998;68(1):171-178. doi:10.1093/ajcn/68.1.171
89. Prual A, Daouda H, Develoux M, Sellin B, Galan P, Hercberg S. Consequences of Schistosoma haematobium infection on the iron status of schoolchildren in Niger. Am J Trop Med Hyg. 1992;47(3):291-297. doi:10.4269/ajtmh.1992.47.291
90. Mansour MM, Francis WM, Farid Z. Prevalence of latent iron deficiency in patients with chronic S. mansoni infection. Trop Geogr Med. 1985;37(2): 124-128.
91. Mahmood T, Rehman AU, Tserenpil G, et al. The Association between Iron-deficiency Anemia and Adverse Pregnancy Outcomes: A Retrospective Report from Pakistan. Cureus. Published online October 7, 2019. doi:10.7759/cureus.5854
92. Freitas SH, Evêncio Neto J, Dória RGS, et al. Aspectos morfológicos, morfométricos e ultraestruturais do baço de ratos após o clampeamento total do pedículo hepático. Arq Bras Med Veterinária E Zootec. 2009;61(6):1314-1321. doi:10.1590/S0102-09352009000600010
93. Galleano M, Tapia G, Puntarulo S, Varela P, Videla LA, Fernández V. Liver preconditioning induced by iron in a rat model of ischemia/reperfusion. Life Sci. 2011;89(7-8):221-228. doi:10.1016/j.lfs.2011.06.005
94. Summers S, Bhattacharyya T, Allan F, et al. A review of the genetic determinants of praziquantel resistance in Schistosoma mansoni: Is praziquantel and intestinal schistosomiasis a perfect match? Front Trop Dis. 2022;3. doi:10.3389/fitd.2022.933097
95. Santini-Oliveira M, Coler RN, Parra J, et al. Schistosomiasis vaccine candidate Sm14/GLA-SE: Phase 1 safety and immunogenicity clinical trial in healthy, male adults. Vaccine. 2016;34(4):586-594. doi:10.1016/j.vaccine.2015.10.027
96. Caldwell N, Afshar R, Baragaña B, et al. Perspective on Schistosomiasis Drug Discovery: Highlights from a Schistosomiasis Drug Discovery Workshop at Wellcome Collection, London, September 2022. ACS Infect Dis. 2023;9(5):1046-1055. doi:10.1021/acsinfecdis.3c00081
97. Abdelgelil NH, Abdellatif MZM, Abdel-Hafeez EH, et al. Effects of iron chelating agent on Schistosoma mansoni infected murine model. Biomed Pharmacother. 2019;109:28-38. doi:10.1016/j.biopha.2018.10.036
98. Abdelgelil NH, Abdellatif MZM, Abdel-Hafeez EH, et al. Effects of iron chelating agent on Schistosoma mansoni infected murine model. Biomed Pharmacother. 2019;109:28-38. doi:10.1016/j.biopha.2018.10.036
99. Salvarani C, Baricchi R, Lasagni D, et al. Effects of desferrioxamine therapy on chronic disease anemia associated with rheumatoid arthritis. Rheumatol Int. 1996;16(2):45-48. doi:10.1007/BF01816434
100. Hanna LS, Mohamed MI, Botros SS. Schistosoma mansoni: IgG reactivity to soluble adult worm antigen preparation (SWAP) in sera of immunized mice with irradiated attenuated and virulent cercariae. J Egypt Soc Parasitol. 1994;24(3):553-568.
101. Abdel-Hakeem SS, Abdel-Samiee MA, Abed GH. An Insight into the Potential Parasitological Effect of Schistosoma mansoni Antigens in Infected Mice: Prophylactic Role of Cercarial Antigen. Microsc Microanal Off J Microsc Soc Am Microbeam Anal Soc Microsc Soc Can. 2020;26(4):708-716. doi:10.1017/S1431927620001695
102. Doughty BL, Goes AM, Parra JC, et al. Granulomatous hypersensitivity to Schistosoma mansoni egg antigens in human Schistosomiasis: I. Granuloma formation and modulation around polyacrylamide antigen-conjugated beads. Mem Inst Oswaldo Cruz. 1987;82(suppl 4):47-54. doi:10.1590/S0074-02761987000800009
103. Candido RRF, Pierre TGS, Jones MK, Graeff-Teixeira C. Evaluation of the immunogenicity of Schistosoma mansoni egg surface. Rev Soc Bras Med Trop. 2017;50(5):652-657. doi:10.1590/0037-8682-0040-2017
104. Farah IO, Johansson M, Lövgren-Bengtson K, Hau J. Schistosoma mansoni in mice: the pattern of primary cercarial exposure determines whether a secondary infection post-chemotherapy elicits a T helper 1- or a T helper 2-associated immune response. Scand J Immunol. 2000;51(3):237-243. doi:10.1046/j.1365-3083.2000.00667.x
105. Xiao S hua, Sun J. Schistosoma hemozoin and its possible roles. Int J Parasitol. 2017;47(4):171-183. doi:10.1016/j.ijpara.2016.10.005
106. Schümann K, Solomons NW. Perspective: What Makes It So Difficult to Mitigate Worldwide Anemia Prevalence? Adv Nutr Int Rev J. 2017;8(3):401-408. doi:10.3945/an.116.013847
107. Kassebaum NJ, GBD 2013 Anemia Collaborators. The Global Burden of Anemia. Hematol Oncol Clin North Am. 2016;30(2):247-308. doi:10.1016/j.hoc.2015.11.002
108. Araujo Costa E, de Paula Ayres-Silva J. Global profile of anemia during pregnancy versus country income overview: 19 years estimative (2000-2019). Ann Hematol. 2023;102(8):2025-2031. doi:10.1007/s00277-023-05279-2
109. Kinyoki D, Osgood-Zimmerman AE, Bhattacharjee NV, et al. Anemia prevalence in women of reproductive age in low- and middle-income countries between 2000 and 2018. Nat Med. 2021;27(10):1761-1782. doi:10.1038/s41591-021-01498-0
110. Sun J, Wu H, Zhao M, Magnussen CG, Xi B. Prevalence and changes of anemia among young children and women in 47 low- and middle-income countries, 2000-2018. EClinicalMedicine. 2021;41:101136. doi:10.1016/j.eclinm.2021.101136
2. Kassebaum NJ, Jasrasaria R, Naghavi M, et al. A systematic analysis of global anemia burden from 1990 to 2010. Blood. 2014;123(5):615-624. doi:10.1182/blood-2013-06-508325
3. Stevens GA, Paciorek CJ, Flores-Urrutia MC, et al. National, regional, and global estimates of anaemia by severity in women and children for 2000–19: a pooled analysis of population-representative data. Lancet Glob Health. 2022;10(5):e627-e639. doi:10.1016/S2214-109X(22)00084-5
4. World Health Organization (WHO), THE GLOBAL HEALTH OBSERVATORY (GHO). Schistosomiasis. Accessed May 16, 2024. https://www.who.int/data/gho/data/themes/topics/schistosomiasis
5. King CH, Galvani AP. Underestimation of the global burden of schistosomiasis. The Lancet. 2018;391(10118):307-308. doi:10.1016/S0140-6736(18)30098-9
6. Kassebaum NJ. The Global Burden of Anemia. Hematol Oncol Clin North Am. 2016;30(2):247-308. doi:10.1016/j.hoc.2015.11.002
7. Lanier JB, Park JJ, Callahan RC. Anemia in Older Adults. Am Fam Physician. 2018;98(7):437-442.
8. Araujo Costa E, De Paula Ayres-Silva J. Global profile of anemia during pregnancy versus country income overview: 19 years estimative (2000–2019). Ann Hematol. Published online May 26, 2023. doi:10.1007/s00277-023-05279-2
9. Kinyoki D, Osgood-Zimmerman AE, Bhattacharjee NV, et al. Anemia prevalence in women of reproductive age in low- and middle-income countries between 2000 and 2018. Nat Med. 2021;27(10):1761-1782. doi:10.1038/s41591-021-01498-0
10. Sun J, Wu H, Zhao M, Magnussen CG, Xi B. Prevalence and changes of anemia among young children and women in 47 low- and middle-income countries, 2000-2018. EClinicalMedicine. 2021;41:101136. doi:10.1016/j.eclinm.2021.101136
11. Leir SA, Foot O, Jeyaratnam D, Whyte MB. Schistosomiasis and associated iron-deficiency anaemia presenting decades after immigration from sub-Saharan Africa. BMJ Case Rep. 2019;12(4):e227564. doi:10.1136/bcr-2018-227564
12. Grotto HZW. Fisiologia e metabolismo do ferro. Rev Bras Hematol E Hemoter. 2010;32:08-17. doi:10.1590/S1516-84842010005000050
13. Koury MJ. Abnormal erythropoiesis and the pathophysiology of chronic anemia. Blood Rev. 2014;28(2):49-66. doi:10.1016/j.blre.2014.01.002
14. Grotto HZW. Metabolismo do ferro: uma revisão sobre os principais mecanismos envolvidos em sua homeostase. Rev Bras Hematol E Hemoter. 2008;30(5). doi:10.1590/S1516-848420080005 00012
15. Dugdale M. ANEMIA. Obstet Gynecol Clin North Am. 2001;28(2):363-382. doi:10.1016/S0889-8545(05)70206-0
16. Vaulont S. Métabolisme du fer. Arch Pédiatrie. 2017;24(5):5S32-5S39. doi:10.1016/S0929-693X(17)24007-X
17. Camaschella Clara. Iron-Deficiency Anemia. N Engl J Med. 2015;372(19):1832-1843. doi:10.1056/NE JMra1401038
18. Milman N, Taylor CL, Merkel J, Brannon PM. Iron status in pregnant women and women of reproductive age in Europe. Am J Clin Nutr. 2017;106(Suppl 6):1655S-1662S. doi:10.3945/ajcn.117.156000
19. WHO Guideline on Use of Ferritin Concentrations to Assess Iron Status in Individuals and Populations. World Health Organization; 2020. Accessed June 3, 2022. http://www.ncbi.nlm.nih.gov/books/NBK569880/
20. Cappellini MD, Santini V, Braxs C, Shander A. Iron metabolism and iron deficiency anemia in women. Fertil Steril. 2022;118(4):607-614. doi:10.1016/j.fertnstert.2022.08.014
21. Gulec S, Anderson GJ, Collins JF. Mechanistic and regulatory aspects of intestinal iron absorption. Am J Physiol-Gastrointest Liver Physiol. 2014;307(4): G397-G409. doi:10.1152/ajpgi.00348.2013
22. Rouault TA. The role of iron regulatory proteins in mammalian iron homeostasis and disease. Nat Chem Biol. 2006;2(8):406-414. doi:10.1038/nchembio807
23. Hentze MW, Muckenthaler MU, Galy B, Camaschella C. Two to Tango: Regulation of Mammalian Iron Metabolism. Cell. 2010;142(1):24-38. doi:10.1016/j.cell.2010.06.028
24. Muckenthaler MU, Rivella S, Hentze MW, Galy B. A Red Carpet for Iron Metabolism. Cell. 2017;168(3):344-361. doi:10.1016/j.cell.2016.12.034
25. Naigamwalla DZ, Webb JA, Giger U. Iron deficiency anemia. Can Vet J Rev Veterinaire Can. 2012;53(3):250-256.
26. Cappellini MD, Musallam KM, Taher AT. Iron deficiency anaemia revisited. J Intern Med. 2020;287(2):153-170. doi:10.1111/joim.13004
27. Pagani A, Nai A, Silvestri L, Camaschella C. Hepcidin and Anemia: A Tight Relationship. Front Physiol. 2019;10. doi:10.3389/fphys.2019.01294
28. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization. Science. 2004;306(5704):2090-2093. doi:10.1126/science.1104742
29. The mutual control of iron and erythropoiesis - Camaschella - 2016 - International Journal of Laboratory Hematology - Wiley Online Library. Accessed May 22, 2024. https://onlinelibrary.wiley.com/doi/10.1111/ijlh.12505
30. Scholl TO. Maternal iron status: relation to fetal growth, length of gestation, and iron endowment of the neonate. Nutr Rev. 2011;69(suppl_1):S23-S29. doi:10.1111/j.1753-4887.2011.00429.x
31. Hercberg S, Preziosi P, Galan P. Iron deficiency in Europe. Public Health Nutr. 2001;4(2B):537-545. doi:10.1079/phn2001139
32. CDC. About Schistosomiasis. Schistosomiasis. March 11, 2024. Accessed May 23, 2024. https://www.cdc.gov/schistosomiasis/about/index.html
33. Ending the neglect to attain the Sustainable Development Goals: A road map for neglected tropical diseases 2021–2030. Accessed May 23, 2024. https://www.who.int/publications/i/item/9789240010352
34. Wang L, Wu X, Li X, et al. Imported Schistosomiasis: A New Public Health Challenge for China. Front Med. 2020;7:553487. doi:10.3389/fmed.2020.553487
35. Kumar V, Gryseels B. Use of praziquantel against schistosomiasis: a review of current status. Int J Antimicrob Agents. 1994;4(4):313-320. doi:10.1016/0924-8579(94)90032-9
36. Fallon PG, Tao LF, Ismail MM, Bennett JL. Schistosome resistance to praziquantel: Fact or artifact? Parasitol Today. 1996;12(8):316-320. doi:10.1016/0169-4758(96)10029-6
37. Santos ET. Schistosoma mansoni: avaliação da fibrose hepática em camundongos submetidos à quimioterapia e reinfectados. Published online 2011. Accessed June 27, 2024. https://www.arca.fiocruz.br/handle/icict/5833
38. Meister I, Leonidova A, Kovač J, Duthaler U, Keiser J, Huwyler J. Development and validation of an enantioselective LC–MS/MS method for the analysis of the anthelmintic drug praziquantel and its main metabolite in human plasma, blood and dried blood spots. J Pharm Biomed Anal. 2016;118:81-88. doi:10.1016/j.jpba.2015.10.011
39. Olveda RM, Acosta LP, Tallo V, et al. Efficacy and safety of praziquantel for the treatment of human schistosomiasis during pregnancy: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2016;16(2):199-208. doi:10.1016/S1473-3099(15)00345-X
40. Malhado M, Pinto DP, Silva ACA, et al. Preclinical pharmacokinetic evaluation of praziquantel loaded in poly (methyl methacrylate) nanoparticle using a HPLC–MS/MS. J Pharm Biomed Anal. 2016;117:405-412. doi:10.1016/j.jpba.2015.09.023
41. Jauréguiberry S, Paris L, Caumes E. Acute schistosomiasis, a diagnostic and therapeutic challenge. Clin Microbiol Infect. 2010;16(3):225-231. doi:10.1111/j.1469-0691.2009.03131.x
42. Olds GR, King C, Hewlett J, et al. Double-blind placebo-controlled study of concurrent administration of albendazole and praziquantel in schoolchildren with schistosomiasis and geohelminths. J Infect Dis. 1999;179(4):996-1003. doi:10.1086/314686
43. Othman AA, Soliman RH. Schistosomiasis in Egypt: A never-ending story? Acta Trop. 2015;148:179-190. doi:10.1016/j.actatropica.2015.04.016
44. Gönnert R, Andrews P. Praziquantel, a new board-spectrum antischistosomal agent. Z Parasitenkd Berl Ger. 1977;52(2):129-150. doi:10.1007/BF00389899
45. Schistosomiasis Chemotherapy - Thétiot‐Laurent - 2013 - Angewandte Chemie International Edition - Wiley Online Library. Accessed June 20, 2024. https://onlinelibrary.wiley.com/doi/abs/10.1002/anie.201208390
46. Frezza TF, Gremião MPD, Zanotti-Magalhães EM, Magalhães LA, de Souza ALR, Allegretti SM. Liposomal-praziquantel: Efficacy against Schistosoma mansoni in a preclinical assay. Acta Trop. 2013;128(1):70-75. doi:10.1016/j.actatropica.2013.06.011
47. Frezza TF, de Souza ALR, Prado CCR, et al. Effectiveness of hyperbaric oxygen for experimental treatment of schistosomiasis mansoni using praziquantel-free and encapsulated into liposomes: assay in adult worms and oviposition. Acta Trop. 2015;150:182-189. doi:10.1016/j.actatropica.2015.07.022
48. Arrúa EC, Ferreira MJG, Salomon CJ, Nunes TG. Elucidating the guest-host interactions and complex formation of praziquantel and cyclodextrin derivatives by 13C and 15N solid-state NMR spectroscopy. Int J Pharm. 2015;496(2):812-821. doi:10.1016/j.ijpharm.2015.11.026
49. Ra ER, Ha T. Novel therapeutic and prevention approaches for schistosomiasis: review. J Adv Res. 2013;4(5). doi:10.1016/j.jare.2012.05.002
50. Dayan AD. Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics. Acta Trop. 2003;86(2):141-159. doi:10.1016/S0001-706X(03)00031-7
51. Olds GR. Administration of Praziquantel to pregnant and lactating women. Prep Control Schistosomiasis Soil-Transm Helminthiasis Twenty-First Century. 2003;86(2):185-195. doi:10.1016/S0001-706X (03)00033-0
52. Dinora GE, Julio R, Nelly C, Lilian YM, Cook HJ. In vitro characterization of some biopharmaceutical properties of praziquantel. Int J Pharm. 2005;295(1):93-99. doi:10.1016/j.ijpharm.2005.01.033
53. Cheng L, Guo S, Wu W. Characterization and in vitro release of praziquantel from poly(ɛ-caprolactone) implants. Int J Pharm. 2009;377(1):112-119. doi:10.1016/j.ijpharm.2009.05.007
54. Katz N, Coelho PMZ. Clinical therapy of schistosomiasis mansoni: The Brazilian contribution. Schisto Res Braz. 2008;108(2):72-78. doi:10.1016/j.actatropica.2008.05.006
55. Novaes MRCG, Souza JP de, Araújo HC de. Síntese do anti-helmíntico praziquantel,a partir da glicina. Quím Nova. 1999;22.
56. Cioli D, Pica-Mattoccia L, Basso A, Guidi A. Schistosomiasis control: praziquantel forever? Mol Biochem Parasitol. 2014;195(1):23-29. doi:10.1016/j.molbiopara.2014.06.002
57. Lim RM, Arme TM, Pedersen AB, Webster JP, Lamberton PHL. Defining schistosomiasis hotspots based on literature and shareholder interviews. Trends Parasitol. 2023;39(12):1032-1049. doi:10.1016/j.pt.2023.09.006
58. Ponzo E, Midiri A, Manno A, Pastorello M, Biondo C, Mancuso G. Insights into the epidemiology, pathogenesis, and differential diagnosis of schistosomiasis. Eur J Microbiol Immunol. 2024;14(2): 86-96. doi:10.1556/1886.2024.00013
59. Friedman JF, Kanzaria HK, McGarvey ST. Human schistosomiasis and anemia: the relationship and potential mechanisms. Trends Parasitol. 2005;21(8): 386-392. doi:10.1016/j.pt.2005.06.006
60. Warren KS, Mahmoud AA, Cummings P, Murphy DJ, Houser HB. Schistosomiasis mansoni in Yemeni in California: duration of infection, presence of disease, therapeutic management. Am J Trop Med Hyg. 1974;23(5):902-909. doi:10.4269/ajtmh.1974.23.902
61. Chabasse D, Bertrand G, Leroux JP, Gauthey N, Hocquet P. [Developmental bilharziasis caused by Schistosoma mansoni discovered 37 years after infestation]. Bull Soc Pathol Exot Filiales. 1985;78(5): 643-647.
62. Mawa PA, Kincaid-Smith J, Tukahebwa EM, Webster JP, Wilson S. Schistosomiasis Morbidity Hotspots: Roles of the Human Host, the Parasite and Their Interface in the Development of Severe Morbidity. Front Immunol. 2021;12:635869. doi:10.3389/fimmu.2021.635869
63. Trippler L, Hattendorf J, Ali SM, et al. Novel tools and strategies for breaking schistosomiasis transmission: study protocol for an intervention study. BMC Infect Dis. 2021;21(1):1024. doi:10.1186/s12879-021-06620-8
64. Díaz AV, Walker M, Webster JP. Reaching the World Health Organization elimination targets for schistosomiasis: the importance of a One Health perspective. Philos Trans R Soc Lond B Biol Sci. 2023;378(1887):20220274. doi:10.1098/rstb.2022.0274
65. Lombardo FC, Pasche V, Panic G, Endriss Y, Keiser J. Life cycle maintenance and drug-sensitivity assays for early drug discovery in Schistosoma mansoni. Nat Protoc. 2019;14(2):461-481. doi:10.1038/s41596-018-0101-y
66. Bergquist R, Zhou XN, Rollinson D, Reinhard-Rupp J, Klohe K. Elimination of schistosomiasis: the tools required. Infect Dis Poverty. 2017;6(1):158. doi:10.1186/s40249-017-0370-7
67. Kajihara N, Hirayama K. The War against a Regional Disease in Japan A History of the Eradication of Schistosomiasis japonica. Trop Med Health. 2011;39(1 Suppl 1):3-44. doi:10.2149/tmh.39-1-suppl_1-3
68. Limpanont Y, Phuphisut O, Reamtong O, Adisakwattana P. Recent advances in Schistosoma mekongi ecology, transcriptomics and proteomics of relevance to snail control. Acta Trop. 2020;202:105244. doi:10.1016/j.actatropica.2019.105244
69. Souza CP de. Molluscicide control of snail vectors of schistosomiasis. Mem Inst Oswaldo Cruz. 1995;90:165-168.
doi:10.1590/S0074-02761995000200007
70. Yuan Y, Xu XJ, Dong HF, Jiang MS, Zhu HG. Transmission control of schistosomiasis japonica: implementation and evaluation of different snail control interventions. Acta Trop. 2005;96(2):191-197. doi:10.1016/j.actatropica.2005.07.014
71. Sun LP, Wang W, Hong QB, et al. Approaches being used in the national schistosomiasis elimination programme in China: a review. Infect Dis Poverty. 2017;6(1):55. doi:10.1186/s40249-017-0271-9
72. Zheng L, Deng L, Zhong Y, Wang Y, Guo W, Fan X. Molluscicides against the snail-intermediate host of Schistosoma: a review. Parasitol Res. 2021;120(10):3355-3393. doi:10.1007/s00436-021-07288-4
73. Cardoso DM, Araújo AF de, Gonçalves S de A, et al. Aspectos espaciais, sociodemográficos, clínicos e temporais da esquistossomose no estado de Minas Gerais entre os anos de 2011 e 2020 / Spatial, socio-demographic, clinical and temporal aspects of schistosomiasis in the state of Minas Gerais between the years of 2011 and 2020. Braz J Dev. 2021;7(8):78130-78143. doi:10.34117/bjdv7n8-165
74. McDonald CJ, Jones MK, Wallace DF, Summerville L, Nawaratna S, Subramaniam VN. Increased iron stores correlate with worse disease outcomes in a mouse model of schistosomiasis infection. PloS One. 2010;5(3):e9594. doi:10.1371/journal.pone.0009594
75. World Health Organization, ed. The Clinical Use of Blood in Medicine, Obstetrics, Paediatrics, Surgery & Anaesthesia, Trauma & Burns. World Health Organization; 2001. https://iris.who.int/handle/10665/42397
76. Scholl TO. Maternal iron status: relation to fetal growth, length of gestation, and iron endowment of the neonate. Nutr Rev. 2011;69 Suppl 1:S23-29. doi:10.1111/j.1753-4887.2011.00429.x
77. WHO, ed. The Clinical Use of Blood in Medicine, Obstetrics, Paediatrics, Surgery & Anaesthesia, Trauma & Burns. World Health Organization; 2001.
78. Farid Z, Patwardhan VN, Darby WJ. Parasitism and anemia. Am J Clin Nutr. 1969;22(4):498-503. doi:10.1093/ajcn/22.4.498
79. Friis H, Mwaniki D, Omondi B, et al. Effects on haemoglobin of multi-micronutrient supplementation and multi-helminth chemotherapy: a randomized, controlled trial in Kenyan school children. Eur J Clin Nutr. 2003;57(4):573-579. doi:10.1038/sj.ejcn.1601568
80. Latham MC, Stephenson LS, Hall A, Wolgemuth JC, Elliot TC, Crompton DW. Parasitic infections, anaemia and nutritional status: a study of their interrelationships and the effect of prophylaxis and treatment on workers in Kwale District, Kenya. Trans R Soc Trop Med Hyg. 1983;77(1):41-48. doi:10.1016/0035-9203(83)90009-3
81. Beasley NM, Tomkins AM, Hall A, et al. The impact of population level deworming on the haemoglobin levels of schoolchildren in Tanga, Tanzania. Trop Med Int Health TM IH. 1999;4(11):744-750. doi:10.1046/j.1365-3156.1999.00486.x
82. Taylor M, Jinabhai CC, Couper I, Kleinschmidt I, Jogessar VB. The effect of different anthelmintic treatment regimens combined with iron supplementation on the nutritional status of schoolchildren in KwaZulu-Natal, South Africa: a randomized controlled trial. Trans R Soc Trop Med Hyg. 2001;95(2):211-216. doi:10.1016/s0035-9203(01)90171-3
83. Sturrock RF, Kariuki HC, Thiongo FW, et al. Schistosomiasis mansoni in Kenya: relationship between infection and anaemia in schoolchildren at the community level. Trans R Soc Trop Med Hyg. 1996;90(1):48-54.
doi:10.1016/s0035-9203(96)90477-0
84. Befidi-Mengue RN, Ratard RC, Beltran G, et al. Impact of Schistosoma haematobium infection and of praziquantel treatment on anaemia of primary school children in Bertoua, Cameroon. J Trop Med Hyg. 1993;96(4):225-230.
85. Stephenson LS, Kinoti SN, Latham MC, Kurz KM, Kyobe J. Single dose metrifonate or praziquantel treatment in Kenyan children. I. Effects on Schistosoma haematobium, hookworm, hemoglobin levels, splenomegaly, and hepatomegaly. Am J Trop Med Hyg. 1989;41(4):436-444. doi:10.4269/ajtmh.1989.41.436
86. McGarvey ST, Aligui G, Graham KK, Peters P, Olds GR, Olveda R. Schistosomiasis japonica and childhood nutritional status in northeastern Leyte, the Philippines: a randomized trial of praziquantel versus placebo. Am J Trop Med Hyg. 1996;54(5):498-502. doi:10.4269/ajtmh.1996.54.498
87. Farid Z, Bassily S, Schulert AR, et al. Blood loss in chronic Schistosoma mansoni infection in Egyptian farmers. Trans R Soc Trop Med Hyg. 1967;61(5): 621-625.
doi:10.1016/0035-9203(67)90124-1
88. Tatala S, Svanberg U, Mduma B. Low dietary iron availability is a major cause of anemia: a nutrition survey in the Lindi District of Tanzania. Am J Clin Nutr. 1998;68(1):171-178. doi:10.1093/ajcn/68.1.171
89. Prual A, Daouda H, Develoux M, Sellin B, Galan P, Hercberg S. Consequences of Schistosoma haematobium infection on the iron status of schoolchildren in Niger. Am J Trop Med Hyg. 1992;47(3):291-297. doi:10.4269/ajtmh.1992.47.291
90. Mansour MM, Francis WM, Farid Z. Prevalence of latent iron deficiency in patients with chronic S. mansoni infection. Trop Geogr Med. 1985;37(2): 124-128.
91. Mahmood T, Rehman AU, Tserenpil G, et al. The Association between Iron-deficiency Anemia and Adverse Pregnancy Outcomes: A Retrospective Report from Pakistan. Cureus. Published online October 7, 2019. doi:10.7759/cureus.5854
92. Freitas SH, Evêncio Neto J, Dória RGS, et al. Aspectos morfológicos, morfométricos e ultraestruturais do baço de ratos após o clampeamento total do pedículo hepático. Arq Bras Med Veterinária E Zootec. 2009;61(6):1314-1321. doi:10.1590/S0102-09352009000600010
93. Galleano M, Tapia G, Puntarulo S, Varela P, Videla LA, Fernández V. Liver preconditioning induced by iron in a rat model of ischemia/reperfusion. Life Sci. 2011;89(7-8):221-228. doi:10.1016/j.lfs.2011.06.005
94. Summers S, Bhattacharyya T, Allan F, et al. A review of the genetic determinants of praziquantel resistance in Schistosoma mansoni: Is praziquantel and intestinal schistosomiasis a perfect match? Front Trop Dis. 2022;3. doi:10.3389/fitd.2022.933097
95. Santini-Oliveira M, Coler RN, Parra J, et al. Schistosomiasis vaccine candidate Sm14/GLA-SE: Phase 1 safety and immunogenicity clinical trial in healthy, male adults. Vaccine. 2016;34(4):586-594. doi:10.1016/j.vaccine.2015.10.027
96. Caldwell N, Afshar R, Baragaña B, et al. Perspective on Schistosomiasis Drug Discovery: Highlights from a Schistosomiasis Drug Discovery Workshop at Wellcome Collection, London, September 2022. ACS Infect Dis. 2023;9(5):1046-1055. doi:10.1021/acsinfecdis.3c00081
97. Abdelgelil NH, Abdellatif MZM, Abdel-Hafeez EH, et al. Effects of iron chelating agent on Schistosoma mansoni infected murine model. Biomed Pharmacother. 2019;109:28-38. doi:10.1016/j.biopha.2018.10.036
98. Abdelgelil NH, Abdellatif MZM, Abdel-Hafeez EH, et al. Effects of iron chelating agent on Schistosoma mansoni infected murine model. Biomed Pharmacother. 2019;109:28-38. doi:10.1016/j.biopha.2018.10.036
99. Salvarani C, Baricchi R, Lasagni D, et al. Effects of desferrioxamine therapy on chronic disease anemia associated with rheumatoid arthritis. Rheumatol Int. 1996;16(2):45-48. doi:10.1007/BF01816434
100. Hanna LS, Mohamed MI, Botros SS. Schistosoma mansoni: IgG reactivity to soluble adult worm antigen preparation (SWAP) in sera of immunized mice with irradiated attenuated and virulent cercariae. J Egypt Soc Parasitol. 1994;24(3):553-568.
101. Abdel-Hakeem SS, Abdel-Samiee MA, Abed GH. An Insight into the Potential Parasitological Effect of Schistosoma mansoni Antigens in Infected Mice: Prophylactic Role of Cercarial Antigen. Microsc Microanal Off J Microsc Soc Am Microbeam Anal Soc Microsc Soc Can. 2020;26(4):708-716. doi:10.1017/S1431927620001695
102. Doughty BL, Goes AM, Parra JC, et al. Granulomatous hypersensitivity to Schistosoma mansoni egg antigens in human Schistosomiasis: I. Granuloma formation and modulation around polyacrylamide antigen-conjugated beads. Mem Inst Oswaldo Cruz. 1987;82(suppl 4):47-54. doi:10.1590/S0074-02761987000800009
103. Candido RRF, Pierre TGS, Jones MK, Graeff-Teixeira C. Evaluation of the immunogenicity of Schistosoma mansoni egg surface. Rev Soc Bras Med Trop. 2017;50(5):652-657. doi:10.1590/0037-8682-0040-2017
104. Farah IO, Johansson M, Lövgren-Bengtson K, Hau J. Schistosoma mansoni in mice: the pattern of primary cercarial exposure determines whether a secondary infection post-chemotherapy elicits a T helper 1- or a T helper 2-associated immune response. Scand J Immunol. 2000;51(3):237-243. doi:10.1046/j.1365-3083.2000.00667.x
105. Xiao S hua, Sun J. Schistosoma hemozoin and its possible roles. Int J Parasitol. 2017;47(4):171-183. doi:10.1016/j.ijpara.2016.10.005
106. Schümann K, Solomons NW. Perspective: What Makes It So Difficult to Mitigate Worldwide Anemia Prevalence? Adv Nutr Int Rev J. 2017;8(3):401-408. doi:10.3945/an.116.013847
107. Kassebaum NJ, GBD 2013 Anemia Collaborators. The Global Burden of Anemia. Hematol Oncol Clin North Am. 2016;30(2):247-308. doi:10.1016/j.hoc.2015.11.002
108. Araujo Costa E, de Paula Ayres-Silva J. Global profile of anemia during pregnancy versus country income overview: 19 years estimative (2000-2019). Ann Hematol. 2023;102(8):2025-2031. doi:10.1007/s00277-023-05279-2
109. Kinyoki D, Osgood-Zimmerman AE, Bhattacharjee NV, et al. Anemia prevalence in women of reproductive age in low- and middle-income countries between 2000 and 2018. Nat Med. 2021;27(10):1761-1782. doi:10.1038/s41591-021-01498-0
110. Sun J, Wu H, Zhao M, Magnussen CG, Xi B. Prevalence and changes of anemia among young children and women in 47 low- and middle-income countries, 2000-2018. EClinicalMedicine. 2021;41:101136. doi:10.1016/j.eclinm.2021.101136